Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Affimed shares more than doubled to $4.12, up 158% from the prior close of $1.60, on the Genentech deal — a clear positive market reaction.
FierceBiotech noted the deal was heavily backloaded — only $96M upfront against $5B in milestones — but praised the Genentech validation as transformational…
Coverage emphasized the Genentech deal as a strategic fit that boosts Affimed's cash runway and validates the ROCK platform as a credible bispecific modality.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Affimed and Genentech (Roche) entered an August 2018 strategic collaboration to develop NK cell engager-based immunotherapeutics. Affimed received $96M upfront and near-term funding plus up to $5.0B in development, regulatory, and commercial milestones across multiple undisclosed solid and hematologic tumor targets. Affimed leads early research using its ROCK platform; Genentech leads clinical development and commercialization worldwide.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Affimed N.V. (this deal) | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |
| Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd. | 2025 | $420M | — |
| Genentech, Inc. (Roche Group) / MaxCyte, Inc. | 2026 | — | — |
← Browse all deals · How we score deals
More: 2018 deals · Genentech, Inc. (Roche Group) deals · Hematology deals